GlassScriptPhysician profile
Steven L Brint
NPI 1518932953
$17,019.68
in general payments reported to CMS, 2019-2025
45 companies · $2,803 in 2025
The $2,803 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,351 · 2020: $1,658 · 2021: $2,658 · 2022: $2,560 · 2023: $2,177 · 2024: $2,812 · 2025: $2,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,540 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,539.74 |
| Education | $252.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,989.78 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Janssen Biotech, INC. | $2,028.15 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,937.81 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,117.06 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $832.30 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $785.90 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $742.00 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $557.08 | 2019-2023 | Linzess |
| Intra-Sana Laboratories | $468.17 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Vivus LLC | $444.13 | 2020-2025 | Pancreaze |
| Intercept Pharmaceuticals, INC. | $402.22 | 2019-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $377.28 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $290.29 | 2023-2024 | Ibsrela |
| Daiichi Sankyo INC. | $288.64 | 2019-2022 | |
| Lilly USA, LLC | $274.09 | 2024-2025 | Omvoh |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $255.00 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $237.88 | 2021-2023 | |
| Madrigal Pharmaceuticals | $237.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Stryker Corporation | $171.83 | 2021 | |
| Genzyme Corporation | $141.57 | 2022-2025 | |
| Shionogi INC | $138.57 | 2019 | |
| Allergan, INC. | $132.73 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $130.25 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $124.87 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $109.58 | 2020-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $79.56 | 2021-2023 | Rebyota |
| Braintree Laboratories, INC. | $78.37 | 2020-2023 | Sutab, Suflave |
| Medtronic, INC. | $75.37 | 2021-2025 | Interstim |
| Celltrion USA INC. | $72.88 | 2024-2025 | Zymfentra, Vegzelma |
| Gilead Sciences, INC. | $70.65 | 2019-2021 | |
| Novo Nordisk INC | $62.25 | 2025 | Wegovy |
| Lucid Diagnostics INC. | $54.49 | 2024-2025 | |
| Sandoz INC. | $47.15 | 2023 | Hyrimoz |
| Amgen INC. | $46.05 | 2022-2023 | Avsola, Amjevita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.91 | 2023-2024 | Cyltezo |
| Aimmune Therapeutics, INC. | $24.66 | 2024 | |
| Endo Pharmaceuticals INC. | $23.53 | 2019 | |
| Pentax of America, INC. | $22.90 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon |
| Pharmacosmos Therapeutics INC. | $20.75 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Evoke Pharma, INC. | $18.46 | 2021 | |
| Capsovision, INC. | $17.32 | 2023 | Capsocam Plus |
| Enterra Medical, INC. | $17.13 | 2025 | |
| Amag Pharmaceuticals, INC. | $15.33 | 2020 | |
| Romark Laboratories, Lc | $6.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Brint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.